Published in Lancet on April 08, 1995
A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet (1998) 4.96
Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet (1996) 2.68
Risk factors for thromboembolic complications in inflammatory bowel disease: the role of hyperhomocysteinaemia. Dig Dis Sci (2005) 0.95
Hyperhomocysteinemia: a new risk factor for central retinal vein occlusion. Trans Am Ophthalmol Soc (2000) 0.94
Homocystinuria: what about mild hyperhomocysteinaemia? Postgrad Med J (1996) 0.89
A cross-sectional study to detect the prevalence of hyperhomocysteinemia in cases of deep vein thrombosis. Indian J Surg (2010) 0.83
Guidelines for the management of thrombophilia. Department of Haematology, The Royal London Hospital, Whitechapel, London, UK. Postgrad Med J (1996) 0.83
Hyperhomocysteinemia and cardiovascular disease: The nutritional perspectives. Indian J Clin Biochem (2000) 0.79
Hyperhomocysteinemia and vascular access thrombosis in hemodialysis patients: a retrospective study. Vasc Health Risk Manag (2013) 0.78
The 894G>T variant in the endothelial nitric oxide synthase gene and spina bifida risk. J Hum Genet (2007) 0.78
Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation. Vasc Med (2015) 0.77
Nutritional hyperhomocysteinaemia. BMJ (1999) 0.77
The case for mild hyperhomocysteinaemia as a risk factor. J Inherit Metab Dis (1997) 0.77
Multiple coronary artery thrombosis in 5,10-methylenetetrahydrofolate reductase gene mutation. Cardiol Res Pract (2011) 0.75
Diagnosis and Treatment of Lower Extremity Deep Vein Thrombosis: Korean Practice Guidelines. Vasc Specialist Int (2016) 0.75
Is homocysteinaemia a risk factor for venous thrombosis and atherosclerotic vascular disease? Lancet (1995) 0.75
Genetics and pulmonary medicine. 4. Pulmonary embolism. Thorax (1998) 0.75
Thrombophilia: a genetic predisposition to thrombosis. Trans Am Clin Climatol Assoc (1999) 0.75
A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet (1995) 17.27
Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature (1994) 9.06
The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA (1995) 7.31
Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med (1995) 6.52
Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood (2000) 6.27
Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet (1994) 5.58
Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet (1995) 5.58
Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet (1994) 5.45
Oral contraceptives and the risk of myocardial infarction. N Engl J Med (2001) 5.18
Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med (1995) 5.16
Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet (1995) 5.10
A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet (1998) 4.96
End of the line for "third-generation-pill" controversy? Lancet (1997) 4.63
The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ (2009) 4.18
Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet (1992) 4.15
Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med (1996) 4.11
Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost (2007) 4.09
Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet (1995) 4.01
Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation (1994) 3.65
Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost (2006) 3.49
Increased fetal loss in women with heritable thrombophilia. Lancet (1996) 3.34
Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. Proc Natl Acad Sci U S A (1991) 3.15
Is publication bias a medical problem? Lancet (1993) 3.04
Assessment and control for confounding by indication in observational studies. J Am Geriatr Soc (1999) 2.71
Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med (1993) 2.70
Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet (1996) 2.68
Oral contraceptives and the risk of venous thrombosis. N Engl J Med (2001) 2.57
High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med (2000) 2.39
Antipsychotic medication and venous thrombosis. Br J Psychiatry (2001) 2.37
Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet (1995) 2.35
Activation of coagulation system during air travel: a crossover study. Lancet (2006) 2.32
Cigarette smoking and the risk of venous thromboembolism: the Tromsø Study. J Thromb Haemost (2012) 2.30
Role of cobalamin intake and atrophic gastritis in mild cobalamin deficiency in older Dutch subjects. Am J Clin Nutr (1998) 2.26
Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation (1998) 2.26
Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease. JAMA (1999) 2.21
Mortality due to pulmonary embolism, myocardial infarction, and stroke among incident dialysis patients. J Thromb Haemost (2012) 2.17
Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT). J Thromb Haemost (2005) 2.13
[The 'Anemia in the midwife practice' standard issued by the Royal Dutch Organisation of Midwives: a risk of not recognizing iron deficiency and hemoglobinopathy]. Ned Tijdschr Geneeskd (2002) 2.13
Patients with type 3 severe von Willebrand disease are not protected against atherosclerosis: results from a multicenter study in 47 patients. Circulation (2004) 2.12
Factor V Leiden: should we screen oral contraceptive users and pregnant women? BMJ (1996) 2.11
Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study) Blood (1995) 2.09
Use of preventive measures for air travel-related venous thrombosis in professionals who attend medical conferences. J Thromb Haemost (2006) 2.06
Current perspective of venous thrombosis in the upper extremity. J Thromb Haemost (2008) 2.06
Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost (1999) 2.04
The family history and inherited thrombophilia. Br J Haematol (1994) 2.03
Mortality and causes of death in patients with hemophilia, 1992-2001: a prospective cohort study. J Thromb Haemost (2006) 2.01
Seasonal variation of venous thrombosis: a consecutive case series within studies from Leiden, Milan and Tromsø. J Thromb Haemost (2012) 2.01
Inherited thrombophilia: Part 1. Thromb Haemost (1996) 2.00
Mortality from venous thromboembolism and myocardial infarction in young women in the Netherlands. Lancet (1996) 1.99
Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect. Lancet (1993) 1.96
Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch Intern Med (1999) 1.95
[Thalidomide in the treatment of refractory multiple myeloma: a Dutch study of 72 patients: an antitumor effect in 45%]. Ned Tijdschr Geneeskd (2002) 1.93
Extrahepatic portal vein thrombosis: aetiology and determinants of survival. Gut (2001) 1.86
Second-generation recombinant factor VIII and inhibitor risk: interpretation of RODIN study findings and implications for patients with haemophilia A. Haemophilia (2013) 1.84
Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol (1998) 1.84
von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis. J Thromb Haemost (2006) 1.84
Maternal hyperhomocysteinemia: a risk factor for neural-tube defects? Metabolism (1994) 1.81
Alloimmunization after blood transfusion in patients with hematologic and oncologic diseases. Transfusion (1999) 1.77
The natural history of chronic hepatitis C in haemophiliacs. Br J Haematol (1996) 1.76
Decreased mortality of ischaemic heart disease among carriers of haemophilia. Lancet (2003) 1.76
Old and new risk factors for upper extremity deep venous thrombosis. J Thromb Haemost (2005) 1.73
Course of the international Normalized Ratio in response to oral vitamin K1 in patients overanticoagulated with phenprocoumon. Br J Haematol (1999) 1.69
The Leiden Thrombophilia Study (LETS). Thromb Haemost (1997) 1.65
Risk of stroke in young women and two prothrombotic mutations: factor V Leiden and prothrombin gene variant (G20210A) Stroke (1998) 1.63
Increased end-stage diabetic nephropathy in Indo-Asian immigrants living in the Netherlands. Diabetologia (2002) 1.63
Usefulness of patient interview in bleeding disorders. Arch Intern Med (1995) 1.62
High levels of factor IX increase the risk of venous thrombosis. Blood (2000) 1.61
Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors. Br J Cancer (2013) 1.60
Is the common 677C-->T mutation in the methylenetetrahydrofolate reductase gene a risk factor for neural tube defects? A meta-analysis. QJM (1997) 1.59
Third-generation oral contraceptive and deep venous thrombosis: from epidemiologic controversy to new insight in coagulation. Am J Obstet Gynecol (1997) 1.59
Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Semin Arthritis Rheum (1998) 1.59
The effects of 5-aza-2'-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes. Leuk Res (2004) 1.58
Risk factor profiles in patients with different clinical manifestations of venous thromboembolism: a focus on the factor V Leiden mutation. Thromb Haemost (1996) 1.58
Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost (2008) 1.57
Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost (2012) 1.56
The RATIO study: oral contraceptives and the risk of peripheral arterial disease in young women. J Thromb Haemost (2003) 1.55
Interferon-alpha as maintenance therapy in patients with multiple myeloma. Ann Oncol (2005) 1.55
Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor. J Thromb Haemost (2007) 1.55
Proof of principle of potential clinical utility of multiple SNP analysis for prediction of recurrent venous thrombosis. J Thromb Haemost (2008) 1.53
5,10-methylenetetrahydrofolate reductase (MTHFR) 677C-->T and 1298A-->C mutations are associated with DNA hypomethylation. J Med Genet (2004) 1.53
Unfiltered coffee increases plasma homocysteine concentrations in healthy volunteers: a randomized trial. Am J Clin Nutr (2000) 1.52
Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels. Haemophilia (2010) 1.51
Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol (2000) 1.51
Primary extranodal and nodal non-Hodgkin's lymphoma. A survey of a population-based registry. Eur J Cancer Clin Oncol (1989) 1.51
The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma. J Thromb Haemost (2004) 1.49
Genome scan of venous thrombosis in a pedigree with protein C deficiency. J Thromb Haemost (2004) 1.49
The role of compliance as a cause of instability in oral anticoagulant therapy. Br J Haematol (1997) 1.48
The molecular basis of cystathionine beta-synthase deficiency in Dutch patients with homocystinuria: effect of CBS genotype on biochemical and clinical phenotype and on response to treatment. Am J Hum Genet (1999) 1.48
Competing interests and controversy about third generation oral contraceptives. BMJ readers should know whose words they read. BMJ (2000) 1.45
Polymorphisms in coagulation factors and the risk of recurrent cardiovascular events in men after a first myocardial infarction. J Thromb Haemost (2008) 1.45
Determinants of plasma homocysteine. Am J Clin Nutr (1998) 1.45
Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood (2000) 1.45
Folate, homocysteine and neural tube defects: an overview. Exp Biol Med (Maywood) (2001) 1.45
Familial thrombophilia and lifetime risk of venous thrombosis. J Thromb Haemost (2004) 1.44
A prospective study of anticardiolipin antibodies as a risk factor for venous thrombosis in a general population (the HUNT study). J Thromb Haemost (2006) 1.43